Menu
Fechar
HRS4R
Vull donar

RAQUEL GUARDEÑO SÁNCHEZ

Oncologia de Precisió de Girona
Firma
RAQUEL GUARDEÑO-SÁNCHEZ
Posició
Investigador/a Pre-doctoral – R1
Investigadors/es Pre-doctorals – R1
Publicacions

Publicacions

0

Survival and adverse events of elderly patients treated with sorafenib for hepatocellular carcinoma

Frontiers in oncology, 2022, 12, 829483-829483 dx.doi.org/10.3389/fonc.2022.829483
0

Evaluating Alternative Ramucirumab Doses as a Single Agent or with Paclitaxel in Second-Line Treatment of Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma: Results from Two Randomized, Open-Label, Phase II Studies

Cancers, 2022, 14 dx.doi.org/10.3390/cancers14051168

García-Velasco A, Zacarías-Pons L, Teixidor H, Valeros M, Liñan R, Carmona-Garcia MC, Puigdemont M, Carbajal W, Guardeño R, Malats N, Duell E, Marcos-Gragera R

Incidence and Survival Trends of Pancreatic Cancer in Girona: Impact of the Change in Patient Care in the Last 25 Years

INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2020, 17 dx.doi.org/10.3390/ijerph17249538

Fort Culillas, R., Carmona Garcia, C., Osca Geli, G., Marcos-Gragera, R., Puigdemont Guinart, M., Biarnes Costa, J., Lopez-Ben, S., Garcia Velasco, A., Guardeno Sanchez, R.

Incidence and survival of pancreatic neuroendocrine tumours in Girona, Spain

ANNALS OF ONCOLOGY, 2020, 31, 169-169 dx.doi.org/10.1016/j.annonc.2020.04.325

Puig-Costa M, Codina-Cazador A, Cortés-Pastoret E, Oliveras-Ferraros C, Cufí S, Flaquer S, Llopis-Puigmarti F, Pujol-Amado E, Corominas-Faja B, Cuyàs E, Ortiz R, Lopez-Bonet E, Queralt B, Guardeño R, Martin-Castillo B, Roig J, Joven J, Menendez JA

Discovery and validation of an INflammatory PROtein-driven GAstric cancer Signature (INPROGAS) using antibody microarray-based oncoproteomics.

Oncotarget, 2014, 5, 1942-1954 dx.doi.org/10.18632/oncotarget.1879

Oliveras-Ferraros C, Vazquez-Martin A, Queralt B, Adrados M, Ortiz R, Cufí S, Hernández-Yagüe X, Guardeño R, Báez L, Martin-Castillo B, Pérez-Martínez MC, Lopez-Bonet E, De Llorens R, Bernadó L, Brunet J, Menendez JA

Interferon/STAT1 and neuregulin signaling pathways are exploratory biomarkers of cetuximab (Erbitux®) efficacy in KRAS wild-type squamous carcinomas: a pathway-based analysis of whole human-genome microarray data from cetuximab-adapted tumor cell-line models.

INTERNATIONAL JOURNAL OF ONCOLOGY, 2011, 39, 1455-1479 dx.doi.org/10.3892/ijo.2011.1155

Oliveras-Ferraros C, Vazquez-Martin A, Cufí S, Queralt B, Báez L, Guardeño R, Hernández-Yagüe X, Martin-Castillo B, Brunet J, Menendez JA

Stem cell property epithelial-to-mesenchymal transition is a core transcriptional network for predicting cetuximab (Erbitux™) efficacy in KRAS wild-type tumor cells.

JOURNAL OF CELLULAR BIOCHEMISTRY, 2011, 112, 10-29 dx.doi.org/10.1002/jcb.22952

Formulari de contacte

Coneix l’IDIBGI!

 menu